Written by : Nikita Saha
September 7, 2023
Lupin has partnered with several entities including Mark Cuban's Cost Plus Drug Company and COPD Foundation, to expand medicine access in the US.
Sharing the news, the company further revealed that this partnership marks a significant milestone in combatting Chronic Obstructive Pulmonary Disease (COPD), along with offering enhanced medicine access to the patients.
The Mumbai-based pharmaceutical stated that it is the only company that offers a generic product that is therapeutically equivalent to Boehringer Ingelheim Pharmaceuticals Spiriva HandiHaler.
Also, this collaboration aims to make Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, more accessible to COPD patients in the United States.
Lupin Limited recently unveiled 'Jeet,' a patient support program promoting heart health. It signifies liberation from disease-induced stress and embarks toward enhanced well-being.
Earlier, Lupin disclosed its acquisition of the diabetes brands'¯Ondero and Ondero Met'¯from Boehringer Ingelheim International GmbH. The acquisition agreement was executed through a cash transaction amounting to ‚¬26 million.
COPD Foundation, launched in 2004, is a non-profit organisation created to enhance the lives of those suffering from COPD, bronchiectasis, and Nontuberculous Mycobacterial (NTM) lung disease.
COPD affects more than 15 million adults in the US making it the fourth leading cause of death in the country.
Recently, COPD partnered with Kivo Health to improve access to virtual pulmonary rehabilitation.
Mark Cuban Cost Plus Drug was established in 2016 and offers safe medicines at the lowest possible price. As a public-benefit enterprise, the company prioritises its social objective of enhancing public health. Earlier this year, the company collaborated with RevSpring to use its payment technology to orchestrate pharmacy billing and give participating pharmacies a way to track prescription sales.